Navigation Links
pHase Pharmaceuticals Announces New Venture
Date:4/22/2010

DALLAS, April 22 /PRNewswire/ -- pHase Pharmaceuticals, LLC announces the launch of its new drug development company.  pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.  

Having developed numerous commercially successful new drugs, the pHase team has now identified an unmet clinical need in a large and growing market.  The principals of pHase have already invested significant capital to initiate the development of a superior form of delivery for a drug in the allergy/immunology space that offers significant clinical, cost and ease of use advantages over the current form of treatment.  In addition, the team has identified and confirmed a streamlined regulatory path that accelerates time to market while decreasing development costs.  

The team consists of Dr. Lynn Yohana Howard, Dr. Nicholas Farina, Edward Walters and Chris Howard.  Members of this team were instrumental in the development of such blockbuster drugs as Aricept, Aciphex, Altocor/Altoprev, Fortamet and Sodium Valproate.  The teams extensive experience in both the formulation of new compounds along with the management of the manufacturing process, clinical trials and FDA approvals, particularly 505 b(2), positions them to succeed in this new venture.

pHase is currently in the process of securing additional capital to fund the 2nd phase of their initial drug development project.  Further information on the team can be found on the company's website www.phasepharma.com.

Carillon Capital Partners is serving as an advisor to pHase and is leading the current effort to raise growth capital for the company.  Carillon Capital Partners is a boutique investment bank, strategic advisor and merchant bank specializing in helping a broad range of companies in the financial services, healthcare, technology and defense industries.  For further information, please see www.carilloncapital.com.


'/>"/>
SOURCE Carillon Capital Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Pa. , May 3, 2016 ACME ... Jack Whelan and Delaware County ... (naloxone HCI) Nasal Spray in all ACME ... U.S. Centers for Disease Control and Prevention (CDC), naloxone has saved ... when police officers in Delaware County were ...
(Date:5/3/2016)... -- Pharmaceutical giant Johnson & Johnson has ... who says its talc-based powder products caused ovarian cancer. ... $5 million in compensatory damages and $50 million in ... ) , This is the second in ... the same court awarded $72 million to the family ...
(Date:5/3/2016)... 3, 2016 Global and ... a basic overview of the industry that covers ... surgical mesh report explores into the international and ... report on Surgical Mesh market spread across 150 ... and figures is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... ... human health, today GrassrootsHealth, a public health promotion and research organization, declared May ... a technology-driven society, and other shifts in cultural behavior over the past several ...
(Date:5/4/2016)... ... May 05, 2016 , ... The talus is the part ... like falls, or traffic accidents can cause the talus bone to be fractured, and ... bone. In a first-of-its-kind procedure using 3D printing technology, internationally renowned orthopedic surgeon ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... donated 100 of its innovative kicking trainers to St. Jude Children’s Research Hospital ... is a durable, lightweight rubber band designed to teach children how to kick ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Camas and Vancouver, WA, has announced the latest beneficiary of their ongoing ... Foundation and their Mammography Program, which provides free mammograms and diagnostic breast ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... products, announced today the introduction of the innovative newly improved Iso-Hip Wrap. ... replacement patients. The plush design enhances comfort and enables the patient to enjoy ...
Breaking Medicine News(10 mins):